Top Mesothelioma Centers in Maryland
The best mesothelioma cancer centers in Maryland include the Sidney Kimmel Comprehensive Cancer Center, the University of Maryland Marlene, Stewart Greenebaum Comprehensive Cancer Center and the Mercy Medical Center’s Institute for Cancer Care. All are National Cancer Institute designated cancer centers, meeting federal standards for cancer research, access to innovative clinical trials and multidisciplinary care.
Patients across the state can also get care at the James M. Stockman Cancer Institute, which has clinical trials, radiation oncology, medical oncology and integrative recovery programs. Patients can consult specialists in cytoreductive therapy with heated chemotherapy, a gold-standard mesothelioma treatment option for complex abdominal cancers.
Each of these Maryland cancer centers provides mesothelioma patients with access to the same level of care offered by leading cancer centers nationwide.
4940 Eastern Ave. Baltimore, MD 21224
22 S. Greene St, Baltimore, MD 21201
345 St Paul Pl, Baltimore, MD 21202
9000 Rockville Pike Bethesda, MD 20892
400 W 7th St, Frederick, MD 21701
Locations of Maryland’s Top Cancer Centers
Patients in Maryland can get top-tier mesothelioma treatment in cities such as Baltimore and Frederick. Both of the state’s National Cancer Institute designated cancer centers are located in Baltimore.
The University of Maryland Medical System offers expert oncology services at cancer centers on the Eastern Shore and in Southern Maryland. The Sidney Kimmel Comprehensive Cancer Center, the University of Maryland Marlene, Stewart Greenebaum Comprehensive Cancer Center and the Mercy Medical Center’s Institute for Cancer Care are located in Baltimore, and the James M Stockman Cancer Institute is located in Frederick.
-
Frederick Regional Health System
400 W 7th St
Frederick, MD 21701 -
Greenebaum Cancer Center at University of Maryland
22 S Greene St
Baltimore, MD 21201- NCI-Designated Cancer Center
-
Mercy Medical Center
345 St Paul Pl
Baltimore, MD 21202 -
National Cancer Institute Center for Cancer Research
9000 Rockville Pike
Bethesda, MD 20892 -
Sidney Kimmel Cancer Center at Johns Hopkins Bayview
4940 Eastern Ave
Baltimore, MD 21224- NCI-Designated Cancer Center
Top Doctors in Maryland
Maryland’s pleural and peritoneal mesothelioma doctors are among the best in the country, with specialists such as Dr. Christine Lau at the University of Maryland School of Medicine leading research into mesothelioma treatment and surgical oncology nationwide. Dr. Lau specializes in thoracic surgery as well as pleural and lung cancer.
Experts like Dr. Richard Battafarano at the Johns Hopkins School of Medicine and Dr. Raffit Hassan at the NCI Center for Cancer Research coordinate clinical trials for new mesothelioma treatments, such as using nivolumab and ipilimumab to replace chemotherapy. Dr. Battafarano specializes in minimally invasive surgical techniques like Video-Assisted Thoracoscopic Surgery. Dr. Hassan is pioneering targeted immunotherapy for mesothelioma, including CAR-T cell therapy.
At Mercy Medical Center in Baltimore, mesothelioma patients can receive care from Dr. Vadim Gushchin, one of the world’s leading peritoneal mesothelioma specialists. Dr. Gushchin directs the HIPEC Program and the Gastrointestinal Oncology Division at Mercy, performing hundreds of procedures using robotic surgery and heated chemotherapy.
Richard Battafarano
Pleural Specialist | Thoracic Surgery
Dr. Richard Battafarano is the regional director of general thoracic surgery at Johns Hopkins Medicine in Baltimore, specializing in the treatment of benign and malignant diseases.
Read Bio
Vadim Gushchin
Peritoneal Specialist | Surgical Oncology
Eminent surgical oncologist Dr. Vadim Gushchin is the director of Mercy Medical Center’s HIPEC Program, Gastrointestinal Oncology department and the Melanoma and Skin Cancer Center.
Read Bio
Raffit Hassan
Pleural Specialist | Peritoneal Specialist | Medical Oncology
Dr. Raffit Hassan is a specialist in pleural mesothelioma at the National Cancer Institute. He is a leader in researching new, effective mesothelioma treatments.
Read Bio
Petr Hausner
Pleural Specialist | Peritoneal Specialist | Medical Oncology
Dr. Petr Hausner is chief of hematology and oncology at the Baltimore VA Medical Center, caring for patients with lung cancer and malignant pleural mesothelioma.
Read Bio
Fabian Johnston
Peritoneal Specialist | Surgical Oncology
Dr. Fabian Johnston is a surgical oncologist who treats peritoneal mesothelioma and other complex abdominal cancers. He chairs the Department of Surgery at Atrium Health Wake Forest Baptist in Winston-Salem, North Carolina.
Read Bio
Christine L. Lau
Pleural Specialist | Thoracic Surgery
Renowned thoracic surgeon Dr. Christine Lau at the University of Maryland School of Medicine is best known for her leadership role in advancing treatment and improving outcomes of patients undergoing lung transplantation.
Read Bio
Armando Sardi
Peritoneal Specialist | Surgical Oncology
Renowned surgical oncologist Dr. Armando Sardi is the medical director of the Institute for Cancer Care at Mercy Medical Center in Baltimore and a specialist in the treatment of peritoneal mesothelioma.
Read BioBegin your search for a doctor in your area.
Get started by selecting location, type, specialty or language.
Clinical Trials in Maryland
In addition to providing innovative mesothelioma treatment, NCI-Designated mesothelioma cancer centers in Maryland perform extensive cancer research through clinical trials. To find open clinical trials, speak with your physician or a Patient Advocate.
Mesothelioma clinical trials offer the opportunity to try emerging therapies, giving patients access to the latest treatments before they’re widely available. Maryland is home to NCI’s Center for Cancer Research, with hundreds of researchers and more than 150 open clinical trials. Some pleural mesothelioma doctors in Maryland are investigating CAR-T cell therapy in Phase 1 clinical trials.
NCT00242723
Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining
Background: * Chromatin is is the structural building block of a chromosome. It is found inside the nucleus of the cell and consists of a complex of DNA and protein. * Cancers of the lung, pleura (lung lining) and esophagus show profound changes in chromatin structure that may affect the course of disease in participants. * A better understanding of these diseases and the genetic changes associated with them may be helpful in developing new treatments for them. Objectives: * To medically evaluate individuals with potential (medically suspicious) or proven cancer of the lung, esophagus, pleura, mediastinum or chest wall, or cancers of other origin that have invaded the lung, and then, to determine eligibility for NCI investigational treatment studies for participants \>18 years of age (adult participants only). * To use clinically obtained biopsies (small pieces of tissue) of tumor and adjacent normal tissue from clinically indicated procedures (standard of care biopsy or surgery), as well as blood and urine samples, from participants with cancer of the lung, esophagus, pleura, mediastinum or chest wall, or cancers of other origin that have invaded the lung, for research into immune and cellular changes of these cancers. Study research includes genetic testing and the growth of laboratory cell lines from participant samples, to examine how genes change drug metabolism. * To permit long-term follow-up of participants with cancer of the lung, esophagus, pleura, mediastinum or chest wall, or cancers of other origin that have invaded the lung, for natural history research on genetics and if the gene expression coincides with clinical response to patient anti-cancer therapies (treatment received at NCI or from participant's own physicians). Eligibility: * Individuals 2 years of age and older with potential (medically suspicious) or proven cancer of the lung, esophagus, pleura, mediastinum or chest wall, or cancers of other origin that have invaded the lung. Note: Individuals \>= 2 years of age and under 18 years of age may only participate in research sample collection if the tissue acquisition is performed during a clinically indicated surgical procedure, and the sampling of tissue, blood or urine does NOT add risk to the clinically indicated procedures. * Participants must have physical examination parameters within acceptable limits by standard of practice guidelines prior to clinically indicated surgical procedure (standard of care biopsy or surgery). Design: * All participants will undergo standard tests to evaluate the stage of their disease, and then, eligibility determination for NCI investigational treatment studies will be made for participants \>18 years of age (adult participants only). * Participants \>18 years of age (adult participants only) who are determined to be eligible for a treatment study at NCI are offered participation in that study. No investigational treatment is administered on this protocol. * Participants \>= 2 years of age (all participants) may receive standard of care treatment at NCI or with their own physician if it is determined that standard of care surgery, radiation, or chemotherapy is more clinically appropriate for that participant's disease status. * Participants who receive standard of care biopsy or surgery (clinically indicated standard staging, surgical intervention, and follow up care) at the NIH Clinical Center are expected to return for a clinical examination visit post-procedure (for instance, 4 weeks after discharge from surgery). After recovery, participants will return to the NIH Clinical Center for study follow-up visits at intervals based on their clinical status (such as every 3 to 36 months) until the end of study participation. * Blood and urine samples are collected from all participants for study research at baseline and study visits until the end of study participation. If participants have additional clinically indicated biopsies or surgeries, resected tissue may be collected for study research (as logistically appropriate). * It is expected that up to 1,559 participants will be enrolled and followed long-term on this study.
Locations
-
Maryland (1)
- National Institutes of Health Clinical Center — Bethesda
NCT03830229
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1
Background: -A gene provides instructions to the body. Mutated genes can sometimes cause cancer. Germline mutations are those people are born with. These mutations in the BAP1 gene can cause mesothelioma and other cancers. Researchers want to study people with germline mutations of BAP1 and other genes known to cause cancer. Objective: -To learn how cancer might develop in people with BAP1 mutations. Eligibility: -People ages 2 and older with a germline mutation in BAP1 Design: * Participants will be screened with: * Medical and family history * Saliva test * Participants with mesothelioma will be in the NIH Group. Participants without mesothelioma can choose to be in either the NIH Group or the Remote Group. * Remote Group participants will have a medical and family history by phone. If they have tumor tissue from a previous surgery, it will be tested. They will be contacted once a year by phone. * NIH Group participants will have a baseline visit. This can take up to 4 days. They may have to stay in the area overnight. The visit will include: * Physical exam * Evaluation of tumor tissue if available * Optional tumor biopsy * Blood tests * Scans: A machine will take pictures of the body. * Photographs of skin lesions or other issues * Skin exam * Eye exam * NIH Group participants will have visits once or twice a year. These will include a physical exam, lab tests, scans, and other tests as needed. * Participants who have a confirmed mutation will be asked to contact any relatives who may be at risk and ask them about joining the study.
Locations
-
Maryland (1)
- National Institutes of Health Clinical Center — Bethesda
NCT01950572
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Background: * Malignant mesothelioma is a malignancy arising from the mesothelial cells of the pleura, peritoneum, pericardium, or tunica vaginalis. * Mesothelioma accounts for 0.10% of deaths annually in the United States. Malignant pleural mesothelioma is the most common of these, comprising of 80% of the cases with an annual incidence of about 2,500 in the United States. * The median survival from diagnosis of pleural mesothelioma is approximately 12 months. The majority of patients present with stage III or IV disease with 85-90% of patients considered unresectable at diagnosis. * Peritoneal mesothelioma has a better prognosis than pleural mesothelioma; nevertheless, patients undergoing therapy for peritoneal mesothelioma have few well-studied treatment options due in large part to the rarity of the disease. * In addition to mesothelioma, mesothelin is highly expressed in several cancers, including pancreatic, biliary adenocarcinomas, gastric and ovarian cancers; mesothelin is also expressed in a significantly larger proportion of thymic carcinoma than thymoma. Objectives: -To allow sample acquisition for use in the study of mesothelioma. Eligibility: * All participants age greater than or equal to 2 years with malignant mesothelioma OR * All participants greater than or equal to 18 years with thymic carcinoma, pancreatic or biliary adenocarcinoma or lung, gastric or ovarian cancers or other solid tumor known to express mesothelin * Must be able and willing to provide informed consent if 18 or over; parent or guardian must be able and willing to provide consent for patients under the age of 18 Design: * Up to 1000 subjects will be enrolled. * Patients will be followed to determine the course of disease and to record any treatment received for mesothelioma. * Patients will undergo sampling of blood, urine, tumor and abnormal body fluids for tissue banking. * Studies which may be performed on banked material include genetic and genomic studies, establishment of cell cultures and immunologic studies.
Locations
-
Maryland (1)
- National Institutes of Health Clinical Center — Bethesda
NCT04847063
Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies
Background: Cytoreductive surgery (CRS) removes tumors in the abdomen. HIPEC is hyperthermic (heated) chemotherapy that washes the inside of the abdomen. CRS with HIPEC may help people with peritoneal carcinomatosis. These are tumors that have spread to the lining of the abdomen from other cancers. Researchers think they can improve the results of CRS with HIPEC treatment on these tumors by choosing the chemotherapy drugs used in HIPEC. Objective: To see if HIPEC after CRS can be improved, using either a model called the SMART (Sustained Microenvironment for Analysis of Resected Tissue) System or using 3-D cell culture (organoid) models, in order to test different chemotherapy drugs on tumors that were surgically removed prior to HIPEC treatment (these models are not attached to the body) versus tumors that were treated with HIPEC while still inside the body before being immediately surgically removed. Eligibility: Adults ages 18 and older who have peritoneal carcinomatosis that cannot be fully removed safely with surgery. Design: Participants will be screened with: Medical history Physical exam Blood and urine tests Electrocardiogram (EKG) Computed tomography (CT) scan Other imaging scans, as needed Tumor biopsy, if needed Laparoscopy (small cuts are made in the abdomen, and a tube with a light and a camera is used to see the organs in the abdomen), if needed Participants will enroll in NIH protocol #13C0176. This allows their tumor samples to be used in future research. Some screening tests may be repeated in the study. Participants will have CRS. As many of their visible tumors will be removed as possible during surgery except for a few specific tumors left to receive the HIPEC treatment. Then they will receive HIPEC and the remaining tumors will be immediately removed. Participants will be in the hospital for 7-21 days after this surgery (CRS with HIPEC). Participants will give tumor, fluid samples (from the abdomen during surgery), blood, saliva, cheek swab, and stool for research. They will complete surveys about their health and quality of life. Participants with peritoneal mesothelioma (mesothelioma primary only) will have genetic (DNA) testing to determine clinical (CLIA level) germline BAP1 status for research use. Participants will have follow-up visits for up to 5 years from CRS with HIPEC. If there is disease progression, participants may have CRS with HIPEC again. Participants will then have follow-up visits for up to 5 years from the date of last CRS with HIPEC.
Locations
-
Maryland (1)
- National Institutes of Health Clinical Center — Bethesda
NCT02012699
Integrated Cancer Repository for Cancer Research
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.
Locations
-
Colorado (1)
- Advent Health — Greenwood Village
-
Connecticut (1)
- Hartford HealthCare Cancer Institute at Manchester Medical Hospital — Manchester
-
Florida (5)
- Florida Hospital Memorial Medical Center — Daytona Beach
- Florida Hospital DeLand — DeLand
- Florida Hospital FISH — Orange City
- Florida Hospital Flagler — Palm Coast
- Tallahassee Memorial Hospital — Tallahassee
-
Illinois (2)
- Rush-Copley Cancer Care Center — Aurora
- Rush-Copley Healthcare Center — Yorkville
-
Indiana (1)
- Parkview Research Center — Fort Wayne
-
Iowa (2)
- Methodist Jennie Edmundson Hospital — Council Bluffs
- Covenant Medical Center, Inc — Waterloo
-
Kansas (1)
- Saint Luke's Cancer Instititute – South — Overland Park
-
Maryland (2)
- Northwest Hospital — Randallstown
- William E. Kahlert Regional Cancer Center — Westminster
-
Massachusetts (1)
- Holyoke Medical Center — Holyoke
-
Minnesota (5)
- Riverwood Healthcare Center — Aitkin
- Essentia Health-St. Joseph's Medical Center — Brainerd
- Essentia Health – Duluth Clinic — Duluth
- St. Luke's Hospital of Duluth — Duluth
- Lake Region Healthcare — Fergus Falls
-
Missouri (6)
- Saint Luke's Cancer Institute, East — Kansas City
- Saint Luke's Cancer Institute — Kansas City
- Saint Luke's Cancer Institute, Kansas City North — Kansas City
- Saint Luke's Cancer Institute, Liberty — Liberty
- North Kansas City Hospital — North Kansas City
- Heartland Regional Medical Center dba Mosaic Life Care — Saint Joseph
-
Montana (1)
- Bozeman Health Deaconess Hospital — Bozeman
-
Nebraska (6)
- Mary Lanning Healthcare, Morrison Cancer Center — Hastings
- Faith Regional Health Services, Carson Cancer Center — Norfolk
- Great Plains Regional Medical Center — North Platte
- Methodist Estabrook Cancer Center — Omaha
- Nebraska Methodist Health System — Omaha
- University of Nebraska Medical Center — Omaha
-
New York (2)
- C.R. Wood Cancer Center, Glens Falls Hospital — Glens Falls
- Faxton St. Luke's Healthcare, Mohawk Valley — Utica
-
North Carolina (1)
- Cape Fear Valley Health System — Fayetteville
-
North Dakota (2)
- Essentia Health — Fargo
- Trinity Hospital Cancer Care Center — Minot
-
Ohio (2)
- Aultman Alliance Community Hospital — Alliance
- Aultman Hospital — Canton
-
Wisconsin (1)
- Bellin Memorial Hospital — Green Bay
NCT05579366
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).
Locations
-
Arizona (2)
- USOR HonorHealth — Phoenix
- USOR Arizona Oncology Associates — Tucson
-
California (4)
- University of California Los Angeles Medical Center — Los Angeles
- University of California, San Diego; Moores Cancer Center — San Diego
- USOR Sansum Clinic — Santa Barbara
- Providence Medical Foundation — Santa Rosa
-
Florida (3)
- USOR Florida Cancer Specialists South — Fort Myers
- USOR Florida Cancer Specialists North — St. Petersburg
- USOR Florida Cancer Specialists East — West Palm Beach
-
Georgia (1)
- Augusta University Georgia Cancer Center — Augusta
-
Kansas (1)
- University of Kansas Medical Center (KUMC) — Westwood
-
Maryland (1)
- USOR Maryland Oncology Hematology — Rockville
-
Massachusetts (2)
- Massachusetts General Hospital — Boston
- Dana Farber Cancer Institute — Boston
-
Michigan (2)
- Karmanos Cancer Institute — Detroit
- START Midwest — Grand Rapids
-
Minnesota (1)
- USOR Minnesota Oncology Hematology — Maplewood
-
New Jersey (1)
- MD Anderson Cancer Center at Cooper- Two Cooper Plaza — Camden
-
Ohio (1)
- Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute — Columbus
-
Oklahoma (1)
- University of Oklahoma – Health Sciences Center — Oklahoma City
-
Oregon (2)
- USOR Oncology Associates of Oregon, P.C. — Eugene
- Compass Oncology – Rose Quarter — Portland
-
Pennsylvania (2)
- USOR Alliance Cancer Specialist — Doylestown
- Allegheny Health Network — Pittsburgh
-
Rhode Island (1)
- Women and Infants Hospital of Rhode Island — Providence
-
Tennessee (2)
- Sarah Cannon Research Institute at Tennessee Oncology — Nashville
- Tennessee Oncology — Nashville
-
Texas (6)
- USOR Texas Oncology — Abilene
- Texas Oncology – Central / South Texas — Austin
- Mary Crowley Cancer Research — Dallas
- USOR Texas Oncology — Fort Worth
- Texas Oncology – Northeast TX — Tyler
- USOR Texas Oncology Gulf Coast — Woodland
-
Utah (1)
- START Mountain Region — West Valley City
-
Virginia (2)
- USOR Virginia Cancer Specialists — Fairfax
- USOR Virginia Oncology Associates — Norfolk
-
Washington (1)
- Swedish Cancer Institute — Seattle
NCT06535607
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
eVOLVE-02 study will evaluate the efficacy and safety of volrustomig as monotherapy or in combination with anti-cancer agents in participants with advanced/metastatic solid tumors.
Locations
-
Maryland (1)
- Research Site — Baltimore
NCT05960773
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
This is a Phase II study to determine the rate of stabilization or disease improvement from investigational decitabine/cedazuridine (INQOVI) treatment in subjects with BRCA1-Associated Protein-1 (BAP1) Cancer Predisposition Syndrome (CPDS) and subclinical, early-stage mesothelioma. Progression-free survival (PFS) will also be determined for treated subjects, and the treatment safety (toxicity) evaluated….
Locations
-
Maryland (1)
- National Institutes of Health Clinical Center — Bethesda
NCT06503146
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
Background: Fibroblast-activation protein (FAP) is an enzyme that appears in high numbers in cancer-associated fibroblasts of certain cancer types. \[18F\]FAPI-74 is a new PET (positron emission tomography) tracer, a substance that is injected into a person s body before an imaging scan. Researchers believe that \[18F\]FAPI-74 PET imaging may be able to visualize cancer more effectively than the approved tracers. If so, the new tracer would make it easier to find FAP-positive tumors in the body. Objective: To see if \[18F\]FAPI-74 PET scan is as good or better than other imaging methods for detecting certain cancers. Eligibility: People aged 18 years or older with one of these cancer types: pancreatic ductal adenocarcinoma (PDAC), cholangiocarcinoma, hepatocellular carcinoma (HCC), gastric cancer, bladder cancer, ovarian cancer, pheochromocytoma/paraganglioma (PPGL), small cell lung cancer (SCLC) or extrapulmonary neuroendocrine cancer (EP-NEC), mesothelioma or sarcoma. Participants must be scheduled or intended to receive treatment for cancer. Design: Participants will have 2 baseline scans: an \[18F\]FAPI-74, and the approved tracer \[18F\]-FDG. The \[18F\]FAPI-74 will be infused through a needle inserted into a vein. About 1 hour later, the participant will undergo imaging. Within 1 week, participants will undergo the same scanning procedures with the approved tracer. If the baseline scan with \[18F\]FAPI-74 shows the tumor(s), scans with this tracer will be repeated when their regular treatment regimen calls for scans again. If the scan with the regular FDG also show tumors, this scan will be repeated within the same week as the repeated \[18F\]FAPI-74 scan. If \[18F\]-FAPi PET scan shows no tumor(s), scans will not be repeated. If the participant's cancer progresses within 2 years, scans may be repeated. Follow-up calls will continue for 2 years.
Locations
-
Maryland (1)
- National Institutes of Health Clinical Center — Bethesda
NCT06885697
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
Background: Mesothelioma is an aggressive cancer that grows in the linings of the body; this can include the membranes that line the heart, lungs, and internal organs. Mesothelin (MSLN) is a protein that appears in high numbers in many tumors, including mesothelioma. Researchers are developing a new treatment that collects a person s own immune cells (T cells); the T cells are genetically modified to target and kill tumor cells with high levels of MSLN. Objective: To test a new treatment (TNhYP218 CAR T cells) in people with solid tumors including mesothelioma. Eligibility: People aged 18 and older with solid tumors including mesothelioma that returned or spread after standard treatment. Design: Participants will be screened. A small piece of tissue will be cut from a tumor (biopsy). The sample will be tested to see if it has enough MSLN. Participants will undergo leukapheresis: Blood will be taken from their body through a vein. The blood will pass through a machine that separates out the T cells. The remaining blood will be returned to the body through a different vein. Participant s T cells will be modified in a lab to produce TNhYP218 CAR T cells. Participants will enter the hospital. For 7 days, they will receive drugs to prepare their bodies for the study treatment. TNhYP218 CAR T cells will be administered into a vein. Participants will remain in the hospital for at least 7 more days. After discharge, participants will have follow-up visits for 5 years. These visits may include imaging scans, blood and heart tests, and a new biopsy. Long-term follow-up will continue another 10 years….
Locations
-
Maryland (1)
- National Institutes of Health Clinical Center — Bethesda
NCT05627960
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
This is a first in human phase 1 study of AG01 an anti-Progranulin/Glycoprotein88 (PGRN/GP88) antibody in patients with advanced solid tumors. AG01 is a recombinant monoclonal antibody expressed in a CHO production cell line. The antibody AG01 binds to human PGRN/GP88, expressed on cancer cells. This study will have a dose escalation portion (1A) to evaluate maximum tolerated dose (MTD) and/or maximum administered dose (MAD), the safety and tolerability of AG01treatment before the dose expansion portion (1B) of the study is initiated. The dose escalation portion of this study (1A) will also be used to determine the recommended phase 2 dose (RP2D) of AG01 antibody to be evaluated in the cohort expansion portion (1B).
Locations
-
Maryland (1)
- University of Maryland Greenebaum Comprehensive Cancer Center — Baltimore
NCT04431024
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome
Background: A germline mutation is a change to a person s genes that is carried through their DNA. These mutations can be passed on from parents to their offspring. Germline mutations in a gene called BAP1 are linked to the development of mesothelioma and other cancers. Researchers want to follow people with these mutations to learn more. Objective: To see if researchers can improve how people who have or are suspected to have a BAP1 mutation are monitored over time. Eligibility: People age 30 and older who are suspected to have a BAP1 germline mutation. Design: Participants will be screened with a personal and family medical history. Their medical records may be reviewed. They will give a blood or saliva sample to test for a BAP1 mutation. They will get genetic counseling. To take part in this study, participants will enroll on 2 to 3 other protocols. Participants will have a physical exam. They may have a tumor biopsy. They will give blood and urine samples. They will have skin and eye exams. Some participants will have video-assisted thoracoscopy to examine the chest and lungs and diagnose suspicious areas. For this, a small camera is inserted into the chest through a small incision. Some participants will have laparoscopy to examine the organs inside the abdomen. For this, a small camera is inserted into the abdomen through a small incision. Participants will have imaging scans of the chest, abdomen, and pelvis. They may have brain scans. Participants will visit the NIH once a year for follow-up exams. Participation lasts indefinitely.
Locations
-
Maryland (1)
- National Institutes of Health Clinical Center — Bethesda
Financial Support for Treatment in Maryland
Financial aid programs in Maryland can help mesothelioma patients cover basic living expenses, transportation, lodging and some medical bills related to cancer treatment. In addition to the state-sponsored Maryland Cancer Fund and regional nonprofits, many Maryland cancer centers offer treatment assistance programs for patients with limited financial means. These programs can alleviate some of the burden of families facing a cancer diagnosis, allowing mesothelioma patients to focus on treatment while reducing finance-related stress.
Finding Financial Aid in Maryland
- Cancer Support Foundation: Mesothelioma patients throughout Maryland can apply for help with heating, fuel and utility payments, including electricity, water and gas bills. The Cancer Support Foundation supports patients in active treatment, including Maryland residents undergoing chemotherapy or recovering from surgery.
- Maryland Cancer Fund: This state program provides one-year grants of up to $20,000 for cancer treatment. To qualify, patients must live in Maryland and have significant financial needs, such as low household income.
- The Bettie Jane Cancer Foundation: Located in Jefferson, this nonprofit supports families facing cancer in Allegheny, Frederick and Washington Counties. The foundation provides financial aid to help cancer patients with medical and non-medical expenses during treatment. This includes everything from insurance co-pays and prescriptions to groceries and transportation costs.
Our Patient Advocates work with people diagnosed with mesothelioma on a case-by-case basis to identify sources of financial aid in Maryland and nationwide. For example, U.S. veterans with mesothelioma can qualify for disability compensation and survivor benefit programs. Our Veterans Department has helped many patients navigate the application process.
Mesothelioma Resources in Maryland
Mesothelioma support services provide resources for patients, caregivers and families at any stage of a diagnosis. Support from organizations like the American Cancer Society and Baltimore Cancer Support Group can include free medical equipment, care services, physical therapy, wellness programs, educational resources and survivorship networks.
Connecting With Cancer Support Programs
- American Cancer Society: ACS Resource Centers in Baltimore and Southeast Maryland help cancer patients with treatment information, wigs, hats and other support services. This national nonprofit also provides links to emotional support groups, financial aid, transportation and lodging, including the Baltimore Hope Lodge, which has 34 rooms close to the city’s leading cancer centers.
- Baltimore Cancer Support Group: Mesothelioma patients living in Baltimore City, Carroll and surrounding counties can find weekly BCSG meetings for cancer survivors. Meetings are available virtually and in person.
- Baltimore City Cancer and Health Equity Coalition: This organization’s database can help Baltimore families facing a mesothelioma diagnosis find low-cost or free local support services, including transportation, nutrition, emergency care and financial aid for utilities and lodging.
- Hope Connections: With locations in Bethesda and Landover, Hope Connections coordinates virtual and in-person support groups for cancer patients, caregivers and bereaved family members. The nonprofit also offers free mind-body services, such as exercise and balance classes, professional acupuncture and gentle Yoga.
- HopeWell Cancer Support: Located just outside of Baltimore, HopeWell offers cancer support services for patients, spouses, caregivers and other family members. Programs include support groups, exercise classes to build muscle strength, Tai Chi, relaxation classes and art therapy.
- Meals on Wheels of Central Maryland: This nonprofit serves 8 Maryland counties by providing nutritional support to cancer patients, helping them maintain their independence and quality of life. Meals on Wheels delivers hot and frozen meals as well as emergency meal kits during weather crises.
Mesothelioma patients living anywhere in Maryland can also access regional support services by dialing 211. The state’s 211 program helps families in need find free local resources, from food pantries and housing assistance to home care and mobility support services.
What Survivors Say About Their Mesothelioma Treatment in Maryland
Many mesothelioma survivors in Maryland have shared their experiences with our Patient Advocates. Their stories emphasize the excellent specialists and medical care available in the state. Mesothelioma patients have benefited from advanced therapy at top cancer centers in Maryland, including cytoreductive surgery with heated chemotherapy at the National Institutes of Health Clinical Center.
Survivor Experience
“My mind wants to do things, but my body isn’t able. There is numbness, still pain related to the surgery. My advice to anyone diagnosed is to find a reason like I have to fight and to live, to keep you going.”
– Albert S. , Pleural Mesothelioma SurvivorVerified Asbestos.com Survivor
Survivor Experience
“I was fortunate to find the right doctor and the right place to be. I asked questions. I did my homework,” she said. “In a way, I was a guinea pig in a new protocol, and it worked… I chose the best possible surgeon, and I told him definitively, “I will be your best patient.”
– Cindy C. , Peritoneal Mesothelioma SurvivorVerified Asbestos.com Survivor
